跳至主要内容
临床试验/NCT05029765
NCT05029765已完成不适用

A 24 Weeks Double-blind Latin-square Trial of Effect of Mediterranean Diet and Probiotics in Adults With Mild Cognitive Impairment

Pablo Pérez Martínez1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年1月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Cognitive change

研究概览

简要总结

Manipulation of the gut microbiota through dietary modification affects brain function, with improvement in patients with cognitive disorders. Combined effect of nutritional intervention with Mediterranean diet and probiotics with potentially healthy growth of germ, affect the evolution of mild cognitive impairment, by the modulation of components related with the axis microbiota-gut-brain: neuropeptides, short-chain fatty acids, markers for oxidative stress and inflammation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age> = 60 years with mild cognitive impairment (Clinical Dementia Rating (CRD) 0.5; Mini Mental Examiantion de Folstein (MMSE)> 23; Repeatable Battery for the Asessment of Neuropsychological Status (RBANS) <= 85)
  • Drugs with a stable dose from a minimum of 4 weeks prior to screening (excluding psychopharmaceuticals and any other that could affect alertness and cognitive ability)
  • Geriatric depression scale score <6
  • Sufficient visual and auditory abilities to carry out the neuropsychological tests. Good health without diseases that prevent the completion of the study.
  • A minimum educational training established for 6 years or similar work history.
  • A familiar informant or close caregiver with a minimum contact with the patient established in 10 hours per week that can accompany the participant to the clinical visits

排除标准

  • Any uncontrolled medical or neurological condition that, in the opinion of the researcher, could contribute to the subject's cognitive impairment (for example, substances abuse, vitamin B12 deficiency, abnormal thyroid function, stroke, or other Cerebral vascular disease, Lewy body dementia, frontotemporal dementia, TBI).
  • A clinically significant psychiatric illness (eg, major depression, schizophrenia, or bipolar affective disorder) in the 6 months prior to screening.
  • Transient ischemic attack or cerebrovascular accident or any unexplained loss of consciousness in 1 year before selection (in case of vascular deficit with cognitive sequelae that may still be reversible).
  • Poorly controlled diabetes mellitus, due to a glycosylated haemoglobin (HbA1c) value of 8% in the selection.
  • History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class 3 or 4), or clinically significant conduction disorders (unstable atrial fibrillation) within 1 year prior to screening.
  • Uncontrolled hypertension defined as the mean of 3 measures of systolic blood pressure / diastolic blood pressure> 165/100 mmHg, and persistent systolic blood pressure / diastolic blood pressure > 180/100 mmHg in the 3 months prior to randomization which were considered by the researcher as an indicative of chronic uncontrolled hypertension.
  • History of seizures in the 10 years prior the selection.
  • Recent history (within 1 year of screening) of alcohol or substance abuse with positive urine test (looking for non-prescription drugs), alcohol or cannabinoids.
  • Patients with chronic diseases will be excluded: severe psychiatric, chronic processes in need of treatment such as chronic kidney failure, chronic liver disease, neoplasms under treatment, chronic obstructive pulmonary disease, endocrinopathies susceptible to decompensation and digestive tract diseases.

结局指标

主要结局

Cognitive change

时间窗: Baseline and 24 weeks after each dietary intervention

Cognitive change in Alzheimer's Disease Assessment Scale-Cognitive-Plus ("ADAS-Cog- Plus"). The total ADAS-Cog-plus score ranges from 0-70 with higher scores suggesting greater impairment.

次要结局

  • Change in inflammatory marker(Baseline and 24 weeks after each dietary intervention)
  • Change in oxidative stress parameters(Baseline and 24 weeks after each dietary intervention)
  • Change in cytokine levels(Baseline and 24 weeks after each dietary intervention)
  • Microbiota pattern(Baseline and 24 weeks after each dietary intervention)
  • Endotoxemia levels(Baseline and 24 weeks after each dietary intervention)
  • Neurofunctional change(Baseline and 24 weeks after each dietary intervention)
  • Modulation of Microbiota-gut-nervous system(Baseline and 24 weeks after each dietary intervention)
  • Neuropeptides modulation(Baseline and 24 weeks after each dietary intervention)

研究者

发起方
Pablo Pérez Martínez
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Pablo Pérez Martínez

Investigator-in-charge at Nutrigenomics Metabolic Syndrome group

Maimónides Biomedical Research Institute of Córdoba

研究点 (1)

Loading locations...

相似试验